Literature DB >> 24056755

HIV: is a vaccine the answer?

Sumit Chawla1, Soumya Swaroop Sahoo1, Rambilas Jain1, Pardeep Khanna1, Bharti Mehta1, Inderjeet Singh1.   

Abstract

Getting to zero: zero new HIV infections, zero deaths from AIDS-related illness, zero discrimination is the theme of World AIDS Day 2012. Given the spread of the epidemic today, getting to zero may sound difficult, but significant progress is underway. The total annual loss for the entire country due to HIV is 7% of GDP, which exceeds India's annual health expenditure in 2004. The additional loss due to loss of labor income and increased medical expenditure as measured by the external transfers, account for 5% of the country's health expenditure and 0.23% of GDP. Given that the HIV incidence rate is only 0.27% in India, these losses are quite staggering. Despite the remarkable achievements in development of anti-retroviral therapies against HIV and the recent advances in new prevention technologies, the rate of new HIV infections continue to outpace efforts on HIV prevention and control. Thus, the development of a safe and effective vaccine for prevention and control of AIDS remains a global public health priority and the greatest opportunity to eventually end the AIDS pandemic.

Entities:  

Keywords:  HIV; immunity; research; vaccine; virus

Mesh:

Substances:

Year:  2013        PMID: 24056755      PMCID: PMC4181026          DOI: 10.4161/hv.26243

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  10 in total

1.  Shooting blanks. "Science" writer Jon Cohen speaks of how the search for an HIV vaccine has strayed. Interview by Bob Roehr.

Authors:  J Cohen
Journal:  IAPAC Mon       Date:  2001-09

2.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

Review 3.  An overview of the relative risks of different sexual behaviours on HIV transmission.

Authors:  Olamide Dosekun; Julie Fox
Journal:  Curr Opin HIV AIDS       Date:  2010-07       Impact factor: 4.283

4.  Mechanism(s) of FIV vaccine protection.

Authors:  R Pu; M C Tellier; J K Yamamoto
Journal:  Leukemia       Date:  1997-04       Impact factor: 11.528

Review 5.  Antiretroviral prophylaxis for occupational exposure to HIV.

Authors:  Clarissa Kripke
Journal:  Am Fam Physician       Date:  2007-08-01       Impact factor: 3.292

Review 6.  Immune responses in HIV-exposed seronegatives: have they repelled the virus?

Authors:  S L Rowland-Jones; A McMichael
Journal:  Curr Opin Immunol       Date:  1995-08       Impact factor: 7.486

7.  Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.

Authors:  Dawn K Smith; Lisa A Grohskopf; Roberta J Black; Judith D Auerbach; Fulvia Veronese; Kimberly A Struble; Laura Cheever; Michael Johnson; Lynn A Paxton; Ida M Onorato; Alan E Greenberg
Journal:  MMWR Recomm Rep       Date:  2005-01-21

Review 8.  Can HIV infection be prevented with a vaccine?

Authors:  A K Joy; C J Dale; S J Kent
Journal:  Drugs R D       Date:  1999-06

Review 9.  Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.

Authors:  Wayne C Koff; Nina D Russell; Mark Walport; Mark B Feinberg; John W Shiver; Salim Abdool Karim; Bruce D Walker; Margaret G McGlynn; Chidi Victor Nweneka; Gary J Nabel
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

Review 10.  Towards an HIV-1 vaccine: lessons from studies in macaque models.

Authors:  E G Hulskotte; A M Geretti; A D Osterhaus
Journal:  Vaccine       Date:  1998 May-Jun       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.